Personal Genome Diagnostics: Megan Bailey, CEO
Personal Genome Diagnostics has appointed Megan Bailey as its new CEO, succeeding Douglas Ward who served as the firm's CEO from 2016. Bailey initially joined PGDx as VP of marketing and was then promoted to chief commercial officer, leading the company’s marketing, sales, customer support, and communications arms in developing and executing global go-to-market strategies. She contributed to the achievement of CE marks for both the elio tissue complete assay and elio plasma resolve products and played a key role in establishing strategic collaborations with organizations such as the Mayo Clinic and PathGroup. Before joining PGDx, Bailey spent more than 14 years at Roche, most recently as that firm's senior director of commercial operations. Prior to that, she held various marketing leadership roles for Roche's tissue diagnostics division.